查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2017493

IgA肾臟病：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

IgA Nephropathy - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场概览

  • 德国市场预计将从 1.16 亿美元成长到 9.5 亿美元（复合年增长率超过 20%）。
  • 推动这一成长的动力在于出现了新的标靶治疗，这些疗法超越了对症治疗，解决了疾病的根本机制。

IgA肾臟病变概述

IgA肾臟病（IgAN）是全球最常见的原发性肾丝球肾炎，其特征是免疫复合物沉积于肾臟，导致进行性肾损伤。此病由IgA1铰链区O-连接糖链的异常糖基化引起，导致循环血液中缺乏半乳糖的IgA1（Gd-IgA1）水平升高。这些异常的IgA1分子可被糖链特异性IgA和IgG自体抗体识别，形成免疫复合物并沉积于肾小球，引起发炎。

IgA是黏膜免疫中的主要抗体，主要以IgA1和IgA2的形式存在，而黏膜相关淋巴组织产生的分泌型IgA则以多聚体的形式存在。在IgA肾病变中，这种免疫调节异常会导致持续性肾功能损害。

临床上，IgA肾病进行性缓慢，约30-40%的患者会在20-30年内发展为末期肾功能衰竭（ESRD）。此病可表现为散发病例（90-95%）或遗传性（5-10%），遗传性病例往往预后严重，且进展为肾衰竭的速度较快。

主要亮点

  • IgAN 是一种慢性进行性肾臟疾病，具有进行性肾病 (ESRD) 的显着长期风险。
  • 预计法国肾臟切片检查病例数将从 1500 例逐渐增加到 1570 例（年复合成长率 0.4%）。

格式化和更新讯息

  • 详细报告（PDF）
  • 市场预测模型（基于微软Excel）
  • 流行病学数据（MS Excel，互动式工具）
  • 高阶主管洞察（PPT简报）
  • 其他功能：定期更新、自订和顾问支援。
  • 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

  • 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
  • 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
  • 未来十年市场收入和病患份额的预测是多少？
  • 哪些因素对市场趋势影响最大？
  • 受访专家对目前和新兴疗法有何看法？
  • 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
  • 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
  • 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

  • G8
    • 我们
    • EU5
      • 法国
      • 德国
      • 义大利
      • 西班牙
      • 英国
    • 日本
    • 中国

大公司

  • Keymed Biosciences Co.Ltd
  • Novartis Pharmaceuticals
  • Biohaven Therapeutics Ltd.
  • Jiangsu HengRui Medicine Co., Ltd.
  • RemeGen Co., Ltd.
  • Chengdu Suncadia Medicine Co., Ltd.
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Beijing Mabworks Biotech Co., Ltd.
  • Calliditas Therapeutics AB
  • Rigerna Therapeutics Co., Ltd.;Rigerna Therapeutics（Beijing）Co., Ltd.
  • Biocity Biopharmaceutics Co., Ltd.
  • HI-Bio, A Biogen Company
  • Purespring Therapeutics Limited
  • Vera Therapeutics, Inc.
  • Visterra, Inc.
  • Otsuka Pharmaceutical Development &Commercialization, Inc.
  • Alpine Immune Sciences Inc, A Subsidiary of Vertex
  • Biogen
  • Sinocelltech Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Travere Therapeutics, Inc.
  • Arrowhead Pharmaceuticals
  • Haisco Pharmaceutical Group Co., Ltd.
  • Suzhou Sanegene Bio Inc.
  • ADARx Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen

目录

第一章：主要调查结果及分析师说明

  • 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

  • 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

  • 重点
  • 发病率/盛行率
  • 已确诊并接受药物治疗的患者人数
  • 合併症
  • 其他相关患者群

第四章 市场规模及预测

  • 重点
  • 市场驱动因素与限制因素
  • 按药物类别分類的趋势
  • 各国具体趋势

第五章 竞争情势

  • 目前疗法
    • 重点
    • 诊断和治疗过程/演算法
    • 主要当前疗法 - 概述和关键意见领袖概述
  • 新兴疗法
    • 重点
    • 值得关注的后期新疗法—概述、市场上市预期和关键意见领袖概述。
    • 值得关注的早期管道

第六章：未满足的需求与目标产品分析

  • 主要未满足的需求以及透过新兴疗法实现的未来可能性
  • TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

简介目录

IgA Nephropathy Market Outlook

Thelansis's "IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

IgA Nephropathy Overview

IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide and is characterized by immune complex deposition in the kidneys, leading to progressive renal damage. The disease is driven by abnormal glycosylation of O-linked glycans in the hinge region of IgA1, resulting in elevated levels of galactose-deficient IgA1 (Gd-IgA1) in circulation. These abnormal IgA1 molecules are recognized by glycan-specific IgA and IgG autoantibodies, forming immune complexes that deposit in the glomeruli and trigger inflammation.

IgA, a key antibody in mucosal immunity, exists primarily as IgA1 and IgA2, with secretory IgA produced by mucosal-associated lymphoid tissues in polymeric form. In IgAN, this immune dysregulation leads to sustained kidney injury.

Clinically, IgAN follows a slow but progressive course, with approximately 30-40% of patients progressing to end-stage renal disease (ESRD) within 20-30 years. The disease may occur as sporadic (90-95%) or familial (5-10%) forms, with familial cases often associated with a more severe prognosis and faster progression to renal failure.

Key Highlights

  • IgAN is a chronic, progressive renal disease with significant long-term ESRD risk
  • France kidney biopsy cases expected to grow modestly from 1.5K to 1.57K (0.4% CAGR)

Market Overview

  • Germany market projected to grow from $116M to $950M (>20% CAGR)
  • Growth driven by emerging targeted therapies addressing underlying disease mechanisms, beyond supportive care

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Keymed Biosciences Co.Ltd
  • Novartis Pharmaceuticals
  • Biohaven Therapeutics Ltd.
  • Jiangsu HengRui Medicine Co., Ltd.
  • RemeGen Co., Ltd.
  • Chengdu Suncadia Medicine Co., Ltd.
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Beijing Mabworks Biotech Co., Ltd.
  • Calliditas Therapeutics AB
  • Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
  • Biocity Biopharmaceutics Co., Ltd.
  • HI-Bio, A Biogen Company
  • Purespring Therapeutics Limited
  • Vera Therapeutics, Inc.
  • Visterra, Inc.
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
  • Alpine Immune Sciences Inc, A Subsidiary of Vertex
  • Biogen
  • Sinocelltech Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Travere Therapeutics, Inc.
  • Arrowhead Pharmaceuticals
  • Haisco Pharmaceutical Group Co., Ltd.
  • Suzhou Sanegene Bio Inc.
  • ADARx Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)